Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia
Heart, Lung and Circulation · 2026
DOI: 10.1016/j.hlc.2026.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2026. Verfasst von Markus P Schlaich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit and RPH Research Foundation, University of Western Australia, Perth, WA, Austra…. Hauptthemen laut MEDLINE: Hypertension, Cost-Benefit Analysis, Kidney, Sympathectomy. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medtronic Inc.
Abstract (Originalsprache)
AIM: Radiofrequency renal denervation (RF RDN) is a guideline-recommended, minimally invasive therapy for patients with uncontrolled, including resistant, hypertension. This analysis assesses the cost-effectiveness of RF RDN compared with optimal medical management for treatment of resistant hypertension in the Australian health care setting on the basis of contemporary clinical data. METHOD: A previously published and validated decision-analytic Markov model was adapted to the Australian health care setting. Primary health states modelled included hypertension, myocardial infarction, stroke, heart failure), angina pectoris/coronary artery disease, end-stage renal disease, and all-cause mortality, with transitions among health states informed by multivariate risk equations. Costs (reported in 2025 Australian Dollar [AUD]$) and utilities were sourced from fee schedules and published literature. The base case modelled a resistant hypertension cohort, informed by registry data, in whom treatment with RF RDN reduced office systolic blood pressure by -5.2 mmHg, based on sham-adjusted results from the SPYRAL HTN-ON MED randomised controlled trial. The primary outcomes included 5-year clinical event rates, in addition to strategy-specific costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio over lifetime. Cost-effectiveness was assessed against an assumed willingness-to-pay threshold of AUD$50,000 per QALY gained. Costs and effects were discounted 5% per annum in accordance with Australian cost-effectiveness guidelines. Extensive scenario and sensitivity analyses were conducted. RESULTS: At 5 years, RF RDN yielded meaningful reductions in clinical events (relative risks of 0.80 for stroke, 0.88 for myocardial infarction, and 0.71 for heart failure). Under the base-case assumptions, RF RDN was associated with incremental costs of AUD$10,396 and QALYs of 0.28, producing a lifetime incremental cost-effectiveness ratio of AUD$36,655 per QALY gained. RF RDN was shown to be cost-effective across the range of scenario and sensitivity analyses explored. CONCLUSIONS: Blood pressure reductions observed with RF RDN are projected to lead to meaningful clinical event reductions that render the therapy a cost-effective adjunctive treatment option for patients with resistant hypertension in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit and RPH Research Foundation, University of Western Australia, Perth, WA, Australia; Department of Cardiology, Royal Perth Hospital, Perth, WA, Austra…
- Wing Tech Inc, Menlo Park, CA, USA.
- Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit and RPH Research Foundation, University of Western Australia, Perth, WA, Australia.
- The Alfred Hospital, Melbourne, Vic, Australia.
- Human Neurotransmitter Laboratory, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.
- Medtronic Italy S.p.A, Milan, Italy.
Förderung
- Medtronic Inc
Zitieren
APA
Schlaich, M. P., Ryschon, A. M., Shetty, S., Walton, A., Esler, M. D., Ciorra, A., Hill, M., & Pietzsch, J. B. (2026). Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia. Heart, Lung and Circulation. https://doi.org/10.1016/j.hlc.2026.04.006
Vancouver
Schlaich MP, Ryschon AM, Shetty S, Walton A, Esler MD, Ciorra A, et al. Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia. Heart, Lung and Circulation. 2026. doi:10.1016/j.hlc.2026.04.006
BibTeX
@article{Schlaich2026,
author = {Schlaich, Markus P and Ryschon, Anne M and Shetty, Sharad and Walton, Antony and Esler, Murray D and Ciorra, Alessandro and Hill, Michelle and Pietzsch, Jan B},
title = {Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia},
journal = {Heart, Lung and Circulation},
year = {2026},
doi = {10.1016/j.hlc.2026.04.006}
}
EUVIMED